Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - roxithromycin, quantity: 150 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; hyprolose; purified talc; magnesium stearate; glucose; titanium dioxide; maize starch; povidone; poloxamer; propylene glycol; hypromellose - adults: for the treatment of mild to moderately severe infections in adults caused by or likely to be caused by susceptible micro-organisms in: acute pharyngitis; tonsillitis and sinusitis. acute bronchitis and acute exacerbations of chronic bronchitis; community acquired pneumonia (including atypical pneumonia). skin and soft tissue infections and non-gonococcal urethritis children: for the treatment of the following mild to moderately severe infections in children caused by or likely to be caused by susceptible micro-organisms: acute pharyngitis; acute tonsillitis; impetigo.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - roxithromycin, quantity: 300 mg - tablet, film coated - excipient ingredients: sodium starch glycollate type b; colloidal anhydrous silica; titanium dioxide; propylene glycol; poloxamer; hypromellose; hyprolose; glucose; maize starch; sodium starch glycollate type a; purified talc; magnesium stearate; povidone - adults: the treatment of the following types of mild to moderately severe infections caused by or likely to be caused by susceptible microorganisms:- * upper respiratory tract infection: acute pharyngitis, tonsillitis and sinusitis. * lower respiratory tract infection: acute bronchitis and acute exacerbations of chronic bronchitis; community acquired pneumonia. * skin and skin structure infections. * nongonococcal urethritis.

Malta - English - Medicines Authority

sanofi malta limited - roxithromycin - film-coated tablet - roxithromycin 150 mg - antibacterials for systemic use

Malta - English - Medicines Authority

kleva s.a. 189 parnithos avenue, 13671 acharnai, attiki, greece - roxithromycin - film-coated tablet - roxithromycin 150 mg - antibacterials for systemic use

Malta - English - Medicines Authority

sanofi s.r.l viale l. bodio, 37/b 20158, milan, italy - roxithromycin - coated tablet - roxithromycin 150 mg - antibacterials for systemic use

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - roxithromycin -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - roxithromycin -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - roxithromycin -

Israel - English - Ministry of Health

unipharm ltd, israel - roxithromycin - tablets - roxithromycin 150 mg - roxithromycin - for the treatment of infections caused by microorganisms sensitive to roxithromycin e.g: ent bronchopulmonary, genital and skin manifestations.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - roxithromycin 50mg - dispersible tablet - 50 mg - active: roxithromycin 50mg excipient: colloidal silicon dioxide crospovidone fumaric acid glycyrrhiza glabra macrogol 6000 magnesium stearate methacrylic acid copolymer microcrystalline cellulose purified talc saccharin sodium sodium hydroxide sodium laureth sulfate strawberry flavour triethyl citrate - rulide d 50mg tablets are indicated for the treatment of the following mild to moderately severe infections in children caused by, or likely to be caused by susceptible micro-organisms: - acute pharyngitis - acute tonsillitis - impetigo